<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00579813</url>
  </required_header>
  <id_info>
    <org_study_id>32677</org_study_id>
    <secondary_id>R01DK071277</secondary_id>
    <nct_id>NCT00579813</nct_id>
  </id_info>
  <brief_title>Mechanisms Underlying Metabolic Syndrome in Obesity</brief_title>
  <official_title>Mechanisms Underlying Metabolic Syndrome in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Kern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the link between obesity and diabetes or
      pre-diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is the most common and powerful force for creating insulin resistance and metabolic
      syndrome, however, the molecular basis of this association is not well understood. In this
      proposal, three independently funded researchers—Philip Kern, MD a clinical investigator, and
      Charlotte Peterson, PhD and Robert McGehee, PhD, with significant experience in muscle and
      adipocyte biology, respectively—will formalize a collaborative effort as a natural extension
      of previous work and shared interests in the fields of obesity, insulin resistance, and
      tissue lipid accumulation. Our overall hypothesis is that insulin resistance in humans stems
      largely from ectopic accumulation of intramyocellular lipid (IMCL) during the development of
      obesity. Further, we hypothesize that excess IMCL accumulation is dependent on secretory
      proteins derived from a complex interplay between adipocytes and macrophages in adipose
      tissue. To test these hypotheses, we will examine the interactions among adipocytes,
      macrophages, and muscle cells isolated and cultured from subjects that are obese with insulin
      resistance and impaired glucose tolerance (IGT), and from some with Type 2 Diabetes. This
      study population has elevated IMCL and is at high risk for obesity complications, but avoids
      the pathophysiologic complications of glucotoxicity. These subjects will be compared to obese
      subjects with normal glucose tolerance (NGT).

      Aim 1 will explore mechanisms that contribute to IMCL and elucidate its role in the
      development of IGT. Cultured muscle cells will be used to determine whether obese subjects
      with IGT versus NGT demonstrate intrinsic differences in muscle gene expression and metabolic
      activity under differing extracellular fatty acid concentrations. Lipid accumulation and
      oxidation, and insulin-mediated glycogen synthesis and signaling will be assessed.

      Aim 2 will determine if the IMCL accumulation is dependent on adipose tissue secretory
      proteins. We will use co-cultures of adipocytes, myoblasts, and adipose stromal vascular
      cells to examine IMCL and the development of insulin resistance.

      Aim 3 will determine whether the stromal fraction from IGT subjects promotes IMCL more
      effectively than that from NGT subjects in co-cultures with muscle cells. We will compare the
      stromal vascular fractions with regard to monocyte/macrophage accumulation and cytokine
      expression.

      Aim 4 will determine if improved glucose tolerance in response to a 10-week treatment with
      pioglitazone results in decreased IMCL and identify cellular mechanisms involved. Co-culture
      studies will also be used with muscle and stromal cells, before and after pioglitazone
      treatment. These experiments will provide mechanistic insight into the link between obesity
      and muscle function leading to metabolic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Sensitivity Using FSIGT</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of Pioglitazone on Changes in BMI</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Muscle Lipid After Pioglitazone</measure>
    <time_frame>At baseline and 10 weeks</time_frame>
    <description>Muscle lipid following biopsy using oil red-O staining.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Fat Inflammation Following Pioglitazone</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Insulin Resistance</condition>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Baseline studies (OGTT, DXA, RMR, FSIGT, and biopsies) on normal control subjects. Oral glucose tolerance tests, body composition assessment, resting metabolic rate, insulin sensitivity measurement with the frequently sampled method and Minimal Model. These studies will establish baseline data in lean subjects on adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition. There is no intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baseline studies (OGTT, DXA, RMR, FSIGT, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment. All of the studies described in arm 1 are repeated after treatment. The subjects in this group have impaired glucose tolerance. After the measurement of adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition, subjects are treated with pioglitazone, working up to 45 mg/day, for 10 weeks. After this time, adipose tissue gene expression, insulin sensitivity, glucose tolerance, metabolic rate and body composition are repeated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age

          -  BMI 28+

          -  diabetes, impaired glucose tolerance or normal glucose tolerance

        Exclusion Criteria:

          -  AST &gt;2x normal

          -  congestive heart failure

          -  history of coronary artery disease

          -  chronic renal insufficiency (creatinine &gt; 1.4mg/dl)

          -  use of gemfibrozil, ACE inhibitors, and angiotensin receptor II blockers, or
             anticoagulants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Kern, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>February 22, 2011</results_first_submitted>
  <results_first_submitted_qc>June 13, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2011</results_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Philip Kern</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>inflammation</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data from this study has been published. Individual (deidentified) data will be shared with other investigators upon request to Dr Kern.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lean Subjects</title>
          <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
        </group>
        <group group_id="P2">
          <title>Obese Subjects</title>
          <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lean Subjects</title>
          <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
        </group>
        <group group_id="B2">
          <title>Obese Subjects</title>
          <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="6"/>
                    <measurement group_id="B2" value="57" spread="2"/>
                    <measurement group_id="B3" value="55" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Insulin Sensitivity Using FSIGT</title>
        <description>The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.</description>
        <time_frame>Baseline and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects, Baseline</title>
            <description>Baseline studies, obese</description>
          </group>
          <group group_id="O2">
            <title>After Pioiglitazone</title>
            <description>10 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Lean Subjects, Baseline</title>
            <description>lean subjects, baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity Using FSIGT</title>
          <description>The frequently sampled intravenous glucose tolerance test (FSIGT) involves the injection of IV glucose and the frequent measurement of glucose and insulin.</description>
          <units>FSIGT units (x10^-4/min/uU/ml)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.53"/>
                    <measurement group_id="O2" value="2.4" spread="1.01"/>
                    <measurement group_id="O3" value="7.02" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effects of Pioglitazone on Changes in BMI</title>
        <description>Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects</description>
        <time_frame>Baseline and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects, Baseline</title>
            <description>Baseline studies, obese</description>
          </group>
          <group group_id="O2">
            <title>After Pioiglitazone</title>
            <description>10 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Lean Subjects, Baseline</title>
            <description>lean subjects, baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Effects of Pioglitazone on Changes in BMI</title>
          <description>Body Mass Index (BMI) is measured at baseline, in lean and obese subjects, and after pioglitazone in obese subjects</description>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="3.89"/>
                    <measurement group_id="O2" value="33.4" spread="4.36"/>
                    <measurement group_id="O3" value="22.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Muscle Lipid After Pioglitazone</title>
        <description>Muscle lipid following biopsy using oil red-O staining.</description>
        <time_frame>At baseline and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects, Baseline</title>
            <description>Baseline studies, obese</description>
          </group>
          <group group_id="O2">
            <title>After Pioiglitazone</title>
            <description>10 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Lean Subjects, Baseline</title>
            <description>lean subjects, baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Muscle Lipid After Pioglitazone</title>
          <description>Muscle lipid following biopsy using oil red-O staining.</description>
          <units>arbitrary units of oil red O staining</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="5.9"/>
                    <measurement group_id="O2" value="4.6" spread="5.9"/>
                    <measurement group_id="O3" value="2.7" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Fat Inflammation Following Pioglitazone</title>
        <description>macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)</description>
        <time_frame>Baseline and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Obese Subjects, Baseline</title>
            <description>Baseline studies, obese</description>
          </group>
          <group group_id="O2">
            <title>After Pioiglitazone</title>
            <description>10 weeks of treatment</description>
          </group>
          <group group_id="O3">
            <title>Lean Subjects, Baseline</title>
            <description>lean subjects, baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fat Inflammation Following Pioglitazone</title>
          <description>macrophages in fat at baseline, in lean and obese participants, and obese after pioglitazone (in obese)</description>
          <units>macrophages per mm2 by CD68 staining</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="6.3"/>
                    <measurement group_id="O2" value="19" spread="9.5"/>
                    <measurement group_id="O3" value="17" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lean Subjects</title>
          <description>Arm 1 was normal subjects on which baseline studies were performed to determine insulin sensitivity, intramyocellular lipid and resting metabolic rate.</description>
        </group>
        <group group_id="E2">
          <title>Obese Subjects</title>
          <description>Baseline studies (Oral glucose tolerance test, Dual energy x-ray absorbiometry, Resting metabolic rate, Frequently sampled intravenous glucose tolerance test, biopsies), then 10 weeks treatment on Pioglitazone. Baseline tests are repeated at the end of medication treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert E. McGehee Jr., Ph.D.</name_or_title>
      <organization>University of Arkansas for Medical Sciences</organization>
      <phone>501-603-1998</phone>
      <email>rem@uams.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

